114 related articles for article (PubMed ID: 31535397)
1. The anticancer effect of the TLR4 inhibition using TAK-242 (resatorvid) either as a single agent or in combination with chemotherapy: A novel therapeutic potential for breast cancer.
Zandi Z; Kashani B; Bashash D; Poursani EM; Mousavi SA; Chahardoli B; Ghaffari SH
J Cell Biochem; 2020 Feb; 121(2):1623-1634. PubMed ID: 31535397
[TBL] [Abstract][Full Text] [Related]
2. Small molecule inhibitor of TLR4 inhibits ovarian cancer cell proliferation: new insight into the anticancer effect of TAK-242 (Resatorvid).
Kashani B; Zandi Z; Bashash D; Zaghal A; Momeny M; Poursani EM; Pourbagheri-Sigaroodi A; Mousavi SA; Ghaffari SH
Cancer Chemother Pharmacol; 2020 Jan; 85(1):47-59. PubMed ID: 31786654
[TBL] [Abstract][Full Text] [Related]
3. Blockade of TLR4 using TAK-242 (resatorvid) enhances anti-cancer effects of chemotherapeutic agents: a novel synergistic approach for breast and ovarian cancers.
Kashani B; Zandi Z; Karimzadeh MR; Bashash D; Nasrollahzadeh A; Ghaffari SH
Immunol Res; 2019 Dec; 67(6):505-516. PubMed ID: 32026322
[TBL] [Abstract][Full Text] [Related]
4. TLR4 blockade using TAK-242 suppresses ovarian and breast cancer cells invasion through the inhibition of extracellular matrix degradation and epithelial-mesenchymal transition.
Zandi Z; Kashani B; Poursani EM; Bashash D; Kabuli M; Momeny M; Mousavi-Pak SH; Sheikhsaran F; Alimoghaddam K; Mousavi SA; Ghaffari SH
Eur J Pharmacol; 2019 Jun; 853():256-263. PubMed ID: 30930249
[TBL] [Abstract][Full Text] [Related]
5. Toll-like receptor 4 signaling pathway is correlated with pathophysiological characteristics of AML patients and its inhibition using TAK-242 suppresses AML cell proliferation.
Baakhlagh S; Kashani B; Zandi Z; Bashash D; Moradkhani M; Nasrollahzadeh A; Yaghmaei M; Mousavi SA; Ghaffari SH
Int Immunopharmacol; 2021 Jan; 90():107202. PubMed ID: 33278749
[TBL] [Abstract][Full Text] [Related]
6. TAK-242 (resatorvid), a small-molecule inhibitor of Toll-like receptor (TLR) 4 signaling, binds selectively to TLR4 and interferes with interactions between TLR4 and its adaptor molecules.
Matsunaga N; Tsuchimori N; Matsumoto T; Ii M
Mol Pharmacol; 2011 Jan; 79(1):34-41. PubMed ID: 20881006
[TBL] [Abstract][Full Text] [Related]
7. Reduced expression of Toll-like receptor 4 inhibits human breast cancer cells proliferation and inflammatory cytokines secretion.
Yang H; Zhou H; Feng P; Zhou X; Wen H; Xie X; Shen H; Zhu X
J Exp Clin Cancer Res; 2010 Jul; 29(1):92. PubMed ID: 20618976
[TBL] [Abstract][Full Text] [Related]
8. Toll-like receptor 4 inhibitor protects against retinal ganglion cell damage induced by optic nerve crush in mice.
Nakano Y; Shimazawa M; Ojino K; Izawa H; Takeuchi H; Inoue Y; Tsuruma K; Hara H
J Pharmacol Sci; 2017 Mar; 133(3):176-183. PubMed ID: 28318829
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological TLR4 Antagonism Using Topical Resatorvid Blocks Solar UV-Induced Skin Tumorigenesis in SKH-1 Mice.
Blohm-Mangone K; Burkett NB; Tahsin S; Myrdal PB; Aodah A; Ho B; Janda J; McComas M; Saboda K; Roe DJ; Dong Z; Bode AM; Petricoin EF; Calvert VS; Curiel-Lewandrowski C; Alberts DS; Wondrak GT; Dickinson SE
Cancer Prev Res (Phila); 2018 May; 11(5):265-278. PubMed ID: 29437671
[TBL] [Abstract][Full Text] [Related]
10. TAK-242 selectively suppresses Toll-like receptor 4-signaling mediated by the intracellular domain.
Kawamoto T; Ii M; Kitazaki T; Iizawa Y; Kimura H
Eur J Pharmacol; 2008 Apr; 584(1):40-8. PubMed ID: 18299127
[TBL] [Abstract][Full Text] [Related]
11. Administration with hyperoside sensitizes breast cancer cells to paclitaxel by blocking the TLR4 signaling.
Sun T; Liu Y; Li M; Yu H; Piao H
Mol Cell Probes; 2020 Oct; 53():101602. PubMed ID: 32447047
[TBL] [Abstract][Full Text] [Related]
12. Deficiency in p53 is required for doxorubicin induced transcriptional activation of NF-кB target genes in human breast cancer.
Dalmases A; González I; Menendez S; Arpí O; Corominas JM; Servitja S; Tusquets I; Chamizo C; Rincón R; Espinosa L; Bigas A; Eroles P; Furriol J; Lluch A; Rovira A; Albanell J; Rojo F
Oncotarget; 2014 Jan; 5(1):196-210. PubMed ID: 24344116
[TBL] [Abstract][Full Text] [Related]
13. Toll-Like Receptor-4 Inhibitor TAK-242 Attenuates Motor Dysfunction and Spinal Cord Pathology in an Amyotrophic Lateral Sclerosis Mouse Model.
Fellner A; Barhum Y; Angel A; Perets N; Steiner I; Offen D; Lev N
Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28763002
[TBL] [Abstract][Full Text] [Related]
14. Ethanol extract of propolis and its constituent caffeic acid phenethyl ester inhibit breast cancer cells proliferation in inflammatory microenvironment by inhibiting TLR4 signal pathway and inducing apoptosis and autophagy.
Chang H; Wang Y; Yin X; Liu X; Xuan H
BMC Complement Altern Med; 2017 Sep; 17(1):471. PubMed ID: 28950845
[TBL] [Abstract][Full Text] [Related]
15. TLR4 Promotes Breast Cancer Metastasis via Akt/GSK3β/β-Catenin Pathway upon LPS Stimulation.
Li J; Yin J; Shen W; Gao R; Liu Y; Chen Y; Li X; Liu C; Xiang R; Luo N
Anat Rec (Hoboken); 2017 Jul; 300(7):1219-1229. PubMed ID: 28296189
[TBL] [Abstract][Full Text] [Related]
16. Investigation of toll-like receptor (TLR) 4 inhibitor TAK-242 as a new potential anti-rheumatoid arthritis drug.
Samarpita S; Kim JY; Rasool MK; Kim KS
Arthritis Res Ther; 2020 Jan; 22(1):16. PubMed ID: 31973752
[TBL] [Abstract][Full Text] [Related]
17. Neuroprotective Effects of Resatorvid Against Traumatic Brain Injury in Rat: Involvement of Neuronal Autophagy and TLR4 Signaling Pathway.
Feng Y; Gao J; Cui Y; Li M; Li R; Cui C; Cui J
Cell Mol Neurobiol; 2017 Jan; 37(1):155-168. PubMed ID: 26961544
[TBL] [Abstract][Full Text] [Related]
18. TAK-242 suppresses lipopolysaccharide-induced inflammation in human coronary artery endothelial cells.
Wei Z; Sun X; Xu Q; Zhang Y; Tian F; Sun H; Zheng H; Dai J
Pharmazie; 2016 Oct; 71(10):583-587. PubMed ID: 29441926
[TBL] [Abstract][Full Text] [Related]
19. Erythropoietin receptor expression and its relationship with trastuzumab response and resistance in HER2-positive breast cancer cells.
Zhang C; Duan X; Xu L; Ye J; Zhao J; Liu Y
Breast Cancer Res Treat; 2012 Dec; 136(3):739-48. PubMed ID: 23117856
[TBL] [Abstract][Full Text] [Related]
20. A novel cyclohexene derivative, ethyl (6R)-6-[N-(2-Chloro-4-fluorophenyl)sulfamoyl]cyclohex-1-ene-1-carboxylate (TAK-242), selectively inhibits toll-like receptor 4-mediated cytokine production through suppression of intracellular signaling.
Ii M; Matsunaga N; Hazeki K; Nakamura K; Takashima K; Seya T; Hazeki O; Kitazaki T; Iizawa Y
Mol Pharmacol; 2006 Apr; 69(4):1288-95. PubMed ID: 16373689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
